Canine parvovirus type-2a (CPV-2a) and type-2b (CPV-2b) have recently been isolated from domestic cats. The pathogenicity of CPV-2b in domestic cats is still unclear. In this study, we performed infection tests to examine the pathogenicity of CPV-2b, FP84 strain, isolated from a domestic cat. The results demonstrated that the CPV strain FP84 is able to infect and replicate well in domestic cats. Two of the 3 cats used in the test died. They showed loss of appetite, diarrhea, leukopenia and dehydration. Since FP84 was found to be virulent to domestic cats, it is necessary to examine the efficacy of inactivated feline panleukopenia virus vaccines against CPV infection in domestic cats. KEY WORDS: canine parvovirus, feline panleukopenia virus, pathogenicity.
Canine parvovirus (CPV) is a pathogenic agent that causes severe hemorrhagic gastroenteritis in dogs. CPV was first isolated from a dog in 1978 in U.S.A. [1] and has since spread rapidly all over the world. The strain was designated CPV type-2 (CPV-2). After the appearance of CPV-2, new antigenic variants termed CPV type-2a (CPV-2a) and CPV type-2b (CPV-2b) were isolated [9, 10, 13] . CPV-2 was completely replaced by CPV-2a and CPV-2b until 1985 [4, 9, 13] . CPV-2a and CPV-2b were recently isolated from domestic cats in Japan, Germany, U.S.A., Taiwan and Vietnam [3, 5-7, 15, 16] . We previously reported that about 3% of parvovirus infections in domestic cats in Japan were caused by CPV-2a or CPV-2b [3] .
The pathogenicity of CPV-2a and CPV-2b in domestic cats is still obscure. Nakamura et al. [8] reported that CPV-2a had the potential to induce disease in cats. On the other hand, Sakamoto et al. [11] and Chalmers et al. [2] reported that CPV-2a and CPV-2b were able to infect cats but did not cause overt clinical signs. In this study, we examined the pathogenicity of FP84 strain, an isolate of CPV-2b from a domestic cat, in domestic cats.
CPV-2b strain FP84, which was isolated from a domestic cat in Tokyo in 2000 [3] , was propagated by 4 passages in crandell feline kidney (CRFK) cells and prepared for the infection study. Three SPF domestic cats (American short hair, 18 weeks old, CSK Research Park, Nagano, Japan) were orally inoculated with 10 6.7 TCID 50 of FP84. The clinical symptoms were recorded after inoculation. Because parvovirus infection causes various clinical signs, the scoring system [8] shown in Table 1 was used. Each domestic cat was bled before inoculation and on various days after inoculation to measure HI titers and the number of white blood cells (WBC). The method used for measurement of HI titers was described previously [12] , and the total number of WBC was measured with a Celltac Automatic Analyzer (Nihon Kohden, Tokyo, Japan).
Rectal swabs were taken to detect viral shedding. Swabs were diluted with 1 ml of phosphate-buffered saline (PBS) containing 0.4% gentamysin. After centrifugation at 4,000 rpm for 10 min at 4°C, 100 µl of each supernatant was inoculated to 5 × 10 5.0 /ml of CRFK cell suspension in a 25 cm 2 flask and incubated at 37°C. The culture fluid was exchanged on the following day and after incubation at 37°C for 6 days, the HA titer of the culture fluid was measured for detection of the virus. In order to detect the virus in organs by PCR, samples were taken on the day of death or 15 days after inoculation. The thymus, heart, lung, liver, spleen, kidneys, mesenteric lymph nodes, duodenum, jejunum and ileum were homogenized to make 10% (w/v) suspension with PBS. After centrifugation at 3,000 rpm for 10 min at 4°C, each sample was assayed by PCR for virus detection. The PCR primers and the condition for the detection of CPV-2a and CPV-2b were described previously [13] .
After challenge with FP84, 2 cats (No. 1 and No. 2) died on the 8th day after inoculation. All of the domestic cats showed loss of appetite, leukopenia, diarrhea and dehydration but no vomiting or fever (Fig. 1) . The mean WBC count reached the lowest level by the 7th day (Fig. 2) . All of the domestic cats started viral shedding on the 5th day post inoculation (Fig. 3) . The viral shedding in No. 1 and No. 2 cats reached the maximum level on the day of death, while virus shedding in No. 3 cat, which survived, stopped on the 10th day. The viruses recovered from swabs were confirmed to be the inoculated virus by PCR and HI test using monoclonal antibodies [10] (data not shown). The HI antibody was first detected on the 5th or 6th day after inoculation, in all of the domestic cats. All of the domestic cats continued viral shedding even after the HI antibody had been detected.
Samples were taken from organs of the domestic cats for virus detection by PCR. The virus was detected in the samples taken from the heart, mesenteric lymph nodes, duodenum, jejunum and ileum of No. 1 and No. 2 cats, which died on the 8th day, while the virus was not detected in any samples taken from organs of No. 3 cat (Table 2 ).
This study demonstrated that FP84 strain was able to infect and replicate well in and was virulent to domestic cats. All of the domestic cats were infected with FP84 strain, shed the virus, and showed loss of appetite, diarrhea, leukopenia and dehydration. The result, together with previous studies, suggests that CPV-2b is circulating among the domestic cat population. We previously reported that the proportions of CPV-2a and CPV-2b in parvovirus infections in domestic cats in Japan were not so high [3] . However, considering the high prevalences of CPV-2a and CPV-2b infections in Taiwan and Vietnam [5] , we are not able to deny the possibility that CPV-2a and CPV-2b are going to replace FPLV in domestic cats in the future. A live FPLV vaccine against CPV infection in domestic cats was confirmed to be effective [2] , however, Steinel et al. [14] reported that inactivated FPLV vaccines are not always effective against CPV infection in domestic cats. Since the majority of FPLV vaccines used in Japan are inactivated vaccines, it is necessary to confirm the efficacy of inactivated FPLV vaccines against CPV infection in domestic cats.
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